MiNA Therapeutics
The company develops small activating RNA (RNAa) therapeutics designed to restore or boost the normal function of genes and protein-modulated pathways. Its proprietary pipeline focuses on genetic medicines, including programs for Sickle Cell Disease and fetal hemoglobin (HbF) induction. The firm also collaborates with pharmaceutical partners to apply its RNAa platform to other therapeutic areas such as neurodegenerative diseases.
Biotechnology
Genetic Medicine
Pharmaceuticals
Funding summary
- Total raised
- €24.9M
- Funding rounds
- 1
Investors in MiNA Therapeutics
Investors on record for MiNA Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like MiNA Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors